Genesis Capital, a private equity firm focused on small and medium-sized companies in Central Europe, has acquired a majority stake in a private outpatient rehabilitation service provider in the Czech Republic, Fyzioterapie s úsměvem.
Ampersand Capital Partners, a life sciences and healthcare-focused private equity firm, has acquired Purna Pharmaceuticals, a Belgian contract development and manufacturing service provider (CDMO) for liquid and semi-solid medicines for pharmaceutical companies, from alternative investment fund manager Creafund.
The UK Competition and Markets Authority (CMA) has ordered US healthcare REIT Welltower to pause the integration process for the 600+ UK care homes it bought in October 2025, as it considers whether controlling all three of the largest for-profit players in the market might raise competition concerns.
DentalMonitoring, a company that has developed an AI-powered system that lets orthodontists monitor their patients’ progress remotely in real time, has raised $100 million in a funding round led by European technology venture capital firm Lazard Elaia Capital, with support from Paris-based private equity firm ISALT.
Sweden-headquartered health and hygiene company Essity has recently secured €400 million in financing from the European Investment Bank, the lending arm of the European Union.
Global private equity firm CVC has purchased the animal health and nutrition (ANH) business of Dutch-Swiss nutrition company dsm-firmenich for €2.2 billion.
Ramsay Health Care, Australia’s biggest private hospital group by revenue, may drop plans to demerge its struggling European business, Ramsay Santé, and instead offload its majority stake to the other main shareholder.
Ramsay appointed investment bank Goldman Sachs in early 2025 to review its options for Santé. Many had expected the group to spin off the European business via an in-species distribution of Sante shares to Ramsay Health Care shareholders. But sources quoted in the Australian press now suggest that option has been dropped.
Juvisé, a France-based speciality pharmaceutical company focusing on essential medicines, has secured €550 million in refinancing from investment firm Hayfin. The financing includes €400 million of existing debt and a new €150 million line for capital expenditure, focusing on future M&A opportunities.
Lenders of Australia’s second-largest private hospital operator, Healthscope, have now approved a plan to restructure the group into a not-for-profit organisation following its liquidation process.
Healthcare Business International users cookies to improve the functionality, performance, and effectiveness of our communications. Detailed information on the use of cookies is provided in our Cookies Policy. By continuing to use this site, or by clicking "I agree" you consent to the use of cookies.